APREA THERAPEUTICS, INC.

DOYLESTOWN, PA · Biotech · Public

WEE1 kinase inhibitor and ATR inhibitor combination therapy for CCNE1-amplified ovarian cancer

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: DOYLESTOWN, PA
Latest Form D: $3.1M, Dec 2025
Total capital: $5.1M

Federal grants: $2M; 2 awards · 2023–2024; Rank in peer group#43 of 326
Private capital raised: $3.1M; 1 Form D · last Dec 2025; 10 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 6 pending

Capital timeline

Latest events

Dec 2025Private capital raisedForm D · SEC · 1st filing$3.1M
Feb 2024Federal grantHealth and Human S · Phase II · Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$1.1M
Feb 2023Federal grantHealth and Human S · Phase II · Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$862K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

34months

from APREA THERAPEUTICS, INC.’s first federal award to its first private round.

First federal award · Feb 2023: Health and Human S · $862K
First Form D · Dec 2025: $3.1M · 1st Form D
Awards before first raise: 2 awards

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grants#43 · top 13%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Oren GiladResearcherExecutive Officer, DirectorLinked by $2M in grants as PI
Bernd B. SeizingerDirectorNamed in SEC Form D filings
Gabriela P. GruiaDirectorNamed in SEC Form D filings
Jean-Pierre P. BizzariDirectorNamed in SEC Form D filings
John P. HamillExecutive OfficerNamed in SEC Form D filings
John B. HennemanDirectorNamed in SEC Form D filings

Show all 10 people

Marc P. DueyDirectorNamed in SEC Form D filings
Michael P. GrissingerDirectorNamed in SEC Form D filings
Richard P. PetersDirectorNamed in SEC Form D filings
Rifat B. PamukcuDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 6

Jul 31, 2025PendingAtr InhibitorsUSPTOApplication 18855713
Aug 1, 2024PendingPyridopyrimidine Derivatives Useful As WEE1 Kinase InhibitorsUSPTOApplication 18565598
PendingMethods For Treating CancerUSPTOApplication PCTUS2025047082

Show all 6 patent records

Atr InhibitorsJul 31, 2025 · Application 18855713Pending
Pyridopyrimidine Derivatives Useful As WEE1 Kinase InhibitorsAug 1, 2024 · Application 18565598Pending
Methods For Treating CancerApplication PCTUS2025047082Pending
Methods For Treating CancerApplication 63696426Pending
Atr InhibitorsApplication PCTUS2023065755Pending
Pharmaceutical Compositions And MethodsApplication PCTUS2022032203Pending

STINGRAY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
IONCOLOGI INCSimilar federal contract value in Biotech · null in contracts
CORNOVUS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
COURAGENE, INC.Similar federal contract value in Biotech · null in contracts
SUNFLOWER THERAPEUTICS PBCSimilar federal contract value in Biotech · null in contracts
NiKang TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.